• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by CAI International, Inc.

    6/29/21 8:21:00 AM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email
    SC 13D 1 tm2120907d1_sc13d.htm SC 13D

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    CAI INTERNATIONAL INC

     

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001

     

     

    (Title of Class of Securities)

     

    12477X106

     

     

    (CUSIP Number of Class of Securities)

     

    Alec N. Litowitz

    Magnetar Capital LLC

    1603 Orrington Ave.

    Evanston, Illinois 60201

    (847) 905-4400

     

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    June 21, 2021

     

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 12477X106 SCHEDULE 13D Page 2 of 10

     

    1.       NAME OF REPORTING PERSON:

     

              Magnetar Financial LLC

     

    2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     


    (a)       ¨

    (b)       x

    3.       SEC USE ONLY

     

    4.       SOURCE OF FUNDS

     

              OO

     

    5.      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)           ¨

     

    6.       CITIZENSHIP OR PLACE OF ORGANIZATION

     

              Delaware

     

    NUMBER OF

    SHARES

    7.       SOLE VOTING POWER

               0

    BENEFICIALLY

    OWNED BY

    8.       SHARED VOTING POWER

               1,271,983

    EACH REPORTING

    PERSON

    9.       SOLE DISPOSITIVE POWER

               0

    WITH

    10.     SHARED DISPOSITIVE POWER

               1,271,983

    11.     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

               1,271,983

     

    12.     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    13.     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

               7.30%

    14.     TYPE OF REPORTING PERSON

     

              IA; OO

     

     

     

     

     

    CUSIP No. 12477X106 SCHEDULE 13D Page 3 of 10

     

    1.       NAME OF REPORTING PERSON:

     

              Magnetar Capital Partners LP

     

    2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     


    (a)       ¨

    (b)       x

    3.       SEC USE ONLY

     

    4.       SOURCE OF FUNDS

     

              OO

     

    5.      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)           ¨

     

    6.       CITIZENSHIP OR PLACE OF ORGANIZATION

     

              Delaware

     

    NUMBER OF

    SHARES

    7.       SOLE VOTING POWER

               0

    BENEFICIALLY

    OWNED BY

    8.       SHARED VOTING POWER

               1,271,983

    EACH REPORTING

    PERSON

    9.       SOLE DISPOSITIVE POWER

               0

    WITH

    10.     SHARED DISPOSITIVE POWER

               1,271,983

    11.     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

               1,271,983

    12.     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES            ¨

     

    13.     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

               7.30%

    14.     TYPE OF REPORTING PERSON

     

              HC; OO

     

     

     

     

    CUSIP No. 12477X106 SCHEDULE 13D Page 4 of 10

     

    1.       NAME OF REPORTING PERSON:

     

              Supernova Management LLC

     

    2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     


    (a)       ¨

    (b)       x

    3.       SEC USE ONLY

     

    4.       SOURCE OF FUNDS

     

              OO

     

    5.      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)           ¨

     

    6.       CITIZENSHIP OR PLACE OF ORGANIZATION

     

              Delaware

     

    NUMBER OF

    SHARES

    7.       SOLE VOTING POWER

               0

    BENEFICIALLY

    OWNED BY

    8.       SHARED VOTING POWER

               1,271,983

    EACH REPORTING

    PERSON

    9.       SOLE DISPOSITIVE POWER

               0

    WITH

    10.     SHARED DISPOSITIVE POWER

               1,271,983

    11.     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

               1,271,983

    12.     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES           ¨

     

    13.     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

               7.30%

    14.     TYPE OF REPORTING PERSON

     

              HC; OO

     

     

     

     

    CUSIP No. 12477X106 SCHEDULE 13D Page 5 of 10

     

    1.       NAME OF REPORTING PERSON:

     

              Alec N. Litowitz

     

    2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     


    (a)       ¨

    (b)       x

    3.       SEC USE ONLY

     

    4.       SOURCE OF FUNDS

     

              OO

     

    5.      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)           ¨

     

    6.       CITIZENSHIP OR PLACE OF ORGANIZATION

     

              United States of America

     

    NUMBER OF

    SHARES

    7.       SOLE VOTING POWER

               0

    BENEFICIALLY

    OWNED BY

    8.       SHARED VOTING POWER

               1,271,983

    EACH REPORTING

    PERSON

    9.       SOLE DISPOSITIVE POWER

               0

    WITH

    10.     SHARED DISPOSITIVE POWER

               1,271,983

    11.     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

               1,271,983

    12.     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES           ¨

     

    13.     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

               7.30%

    14.     TYPE OF REPORTING PERSON

     

              HC; IN

     

     

     

     

     

    SCHEDULE 13D

     

    item 1.security and issuer

     

    This Schedule 13D (this “Statement”) relates to the common stock, no par value (the “Shares”), of CAI INTERNATIONAL INC, a company incorporated in Delaware (the “Company”). The principal executive offices of the Company is Stewart Tower 1, Market Plaza, Suite 2400, San Francisco, CA 94105.

     

    Item 2.identity and background

     

    (a)            The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”).

     

    This Statement relates to Shares held for the accounts of each of (i)  Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii) Magnetar Constellation Fund II-PRA LP, a Delaware limited partnership (“Constellation Fund”), and (iii) Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), collectively (the “Funds”).

     

    Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Litowitz.

     

    (b)            The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

     

    (c)            Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Litowitz is a citizen of the United States of America, manager of Supernova Management and Chief Executive Officer of Magnetar Financial.

     

    (d)            None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)            None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)            Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Litowitz is a citizen of the United States of America.

     

    Item 3.source and amount of funds or other consideration

     

    The aggregate amount of funds used by the Reporting Persons in purchasing the 1,271,983 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $71,049,963.15 (excluding commissions and other execution-related costs).

     

    ITEM 4.PURPOSE OF TRANSACTION

     

    The Reporting Persons acquired the 1,271,983 Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

     

    Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

     

    Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    The Company reported in their Form 8-K filed on June 17, 2021 that 17,341,524 Shares were issued and outstanding as of June 14, 2021.

     

    (a)            As of the close of business June 28, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,271,983 Shares, which consisted of (i) 719,093 Shares held for the benefit of PRA Master Fund, (ii) 400,560 Shares held for the benefit of Constellation Fund; and (iii) 152,330 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 7.30% of the Shares.

     

    (b)            As of the close of business June 28, 2021, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 1,271,983 Shares, which consisted of (i) 719,093 Shares held for the benefit of PRA Master Fund, (ii) 400,560 Shares held for the benefit of Constellation Fund; and (iii) 152,330 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 7.30% of the Shares.

     

     

     

     

    (c)            Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on the NYSE and various other trading markets.

     

    As disclosed by the Company in the 8-K filed with the SEC on June 17, 2021:

     

    On June 17, 2021 (the “Signing Date”), CAI International, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Mitsubishi HC Capital Inc., a Japanese corporation (“Parent” or “MHC”), and Cattleya Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), relating to the proposed acquisition of the Company by Parent.

     

    The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into the Company (the “Merger”) with the Company continuing as the surviving corporation in the Merger, and, at the effective time of the Merger (the “Effective Time”):

    ·each share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), that is issued and outstanding immediately prior to the Effective Time (other than Excluded Shares (as defined in the Merger Agreement)) will cease to be outstanding and will be converted into the right to receive $56.00, in cash, without interest, subject to deductions of any applicable withholding taxes (the “Common Merger Consideration”);
    ·each share of the Company’s 8.50% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), that is issued and outstanding immediately prior to the Effective Time, other than Excluded Shares, will be converted into the right to receive an amount equal to the sum of: (i) the liquidation preference of $25.00 per share, plus (ii) the aggregate amount of all accrued and unpaid dividends on such Series A Preferred Stock as of the Effective Time, in cash, without interest, subject to deductions of any applicable withholding taxes; and
    ·each share of the Company’s 8.50% Series B Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”) that is issued and outstanding immediately prior to the Effective Time, other than Excluded Shares, will be converted into the right to receive an amount equal to the sum of: (i) the liquidation preference of $25.00 per share, plus (ii) the aggregate amount of all accrued and unpaid dividends on such Series B Preferred Stock as of the Effective Time, in cash, without interest, subject to deductions of any applicable withholding taxes.

     

    (d)            No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any Shares that are beneficially owned by the Reporting Persons.

     

    Item 6.contracts, arrangements, understandings or relationships with respect to the securities of the issuer

     

    Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

     

     

     

     

    Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

     

     

     

     

    ITEM 7.MATERIAL TO BE FILED AS EXHIBITS
    Exhibit No.Description

     

    99.1Joint Filing Agreement, dated as of June 29, 2021 among the Reporting Persons.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 29, 2021

     

     magnetar financial llc
       
     By: Magnetar Capital Partners LP, its Sole Member
       
       
    By:/s/ Alec N. Litowitz

       Name:Alec N. Litowitz
       Title:Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      magnetar capital partners LP
         
         
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      supernova management llc
         
         
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager
         
         
      /s/ Alec N. Litowitz
      Alec N. Litowitz

     

     

     

     

    SCHEDULE A

     

    Funds

     

    Date   Number of Shares  Bought   Price Per Share($) (1)(2) 
     6/18/2021    793,844    55.79144 (3)
     6/21/2021    196.864    55.99849 (4)
     6/22/2021    210,697    55.93791 (5)
     6/23/2021    70,062    55.97064 (6)
     6/24/2021    516    55.82854(7)

     

    (1)Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average purchase price of $55.79144 per share, at prices ranging from $55.67 to $56.05 per share.

    (4) Reflects a weighted average purchase price of $55.99849 per share, at prices ranging from $55.80 to $56.05 per share.

    (5) Reflects a weighted average purchase price of $55.93791 per share, at prices ranging from $55.82 to $56.05 per share.

    (6) Reflects a weighted average purchase price of $55.97064 per share, at prices ranging from $55.88 to $56.04 per share.

    (7) Reflects a weighted average purchase price of $55.82854 per share, at prices ranging from $55.75 to 56.05 per share.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.  Description

     

    99.1  Joint Filing Agreement, dated as of June 29, 2021, among the Reporting Persons.

     

     

     

    Get the next $CAI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    7/14/2025$33.00Outperform
    Evercore ISI
    7/14/2025$32.00Buy
    TD Cowen
    7/14/2025$38.00Buy
    BTIG Research
    7/14/2025$34.00Buy
    Citigroup
    7/14/2025$32.00Outperform
    Wolfe Research
    More analyst ratings

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Poste George exercised 125,000 shares at a strike of $2.44 and covered exercise/tax liability with 139,517 shares, decreasing direct ownership by 6% to 220,237 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:07:56 PM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley covered exercise/tax liability with 63,509 shares, decreasing direct ownership by 12% to 460,377 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:07:06 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Halbert David D covered exercise/tax liability with 141,956 shares, decreasing direct ownership by 6% to 2,295,133 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    8/13/25 8:05:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

    IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. MI Cancer Seek is the first and only test to combine whole exome sequencing (WES) and whole transcriptome sequencing (WTS) with FDA-approved CDx indications for solid tumor profiling in

    8/15/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups

    IRVING, Texas, Aug. 13, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, published results in Breast Cancer Research comparing the effectiveness and optimal sequencing of two antibody-drug conjugates, trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in HER2-negative breast cancer patients. The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking S

    8/13/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Reports Second Quarter 2025 Financial Results

    IRVING, Texas, Aug. 12, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported total revenue of $181.4 million, an increase of 81.3% over the corresponding prior year period.Completed 50,032 clinical therapy selection cases, an increase of 22.0% over corresponding prior year period.Reported gross margin of 62.7%, a 2,514 bps improvement over corresponding prior year period.Reported net loss

    8/12/25 4:05:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Caris Life Sciences with a new price target

    BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00

    7/14/25 8:49:47 AM ET
    $CAI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Caris Life Sciences with a new price target

    Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00

    7/14/25 8:49:26 AM ET
    $CAI
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Caris Life Sciences with a new price target

    Guggenheim initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $32.00

    7/14/25 8:49:05 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Brille Brian J bought $630,000 worth of shares (30,000 units at $21.00) and was granted 132,428 shares (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:30:15 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

    IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a

    7/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Declares Quarterly Dividend

    CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that CAI's Board of Directors declared a cash dividend of $0.30 per common share payable on September 27, 2021 to shareholders of record as of September 10, 2021. About CAI International, Inc. CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States. Additional Information and Where to Find It This communication relates to the proposed merger involving the Co

    8/27/21 5:49:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    CAI International, Inc. Enters into Definitive Agreement to be Acquired by Mitsubishi HC Capital Inc.

    Purchase Price of $56.00 per Common Share in Cash CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement with MHC (the "Merger Agreement"), MHC will acquire all of CAI's outstanding and fully diluted common stock in an all-cash transaction for $56.00 per share, which represents a total equity value of approximately $1.1 billion, consisting of $104 million (par value) of preferred stock and $986 million of common stock equity value, assuming a fully-diluted share count

    6/17/21 7:34:00 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    8/14/25 4:05:14 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    8/13/25 4:05:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Caris Life Sciences Inc.

    10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)

    8/12/25 4:59:53 PM ET
    $CAI
    Medical Specialities
    Health Care